Company intelligence / Profile preview
4M Therapeutics
Cambridge, Massachusetts, United States4mtx.net ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
4M Therapeutics has developed a pipeline of small molecule and peptide therapeutics targeting key pathways involved in neuroplasticity, neurogenesis, and neuroinflammation. Their lead candidate, a selective GSK3β inhibitor (4MT2001), aims to provide a safer alternative to lithium for bipolar disorder. The company has filed provisional patents on two assets and expects its lead program to enter clinical trials in the near future. No published clinical results yet; programs are preclinical as of early/mid–2025.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesPeptides
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on 4M Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4M Therapeutics.